MedTrace Logo

A Study of PN20 in Healthy Adult Volunteers

NCT06523088 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-03-13

No results posted yet for this study

Summary

The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are:

* Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a look-alike substance that contains no drug) to see if PN20 is safe.

Participants will

* Receive a single dose injection of PN20 or placebo according to weight,
* Stay in hospital for assessment.

Conditions

  • Chemotherapy-induced Thrombocytopenia
  • Immune Thrombocytopenic Purpura

Interventions

DRUG

PN20

Six dose levels of PN20 will be evaluated

DRUG

Placebo

Placebo of PN20

Sponsors & Collaborators

  • Chongqing Peg-Bio Biopharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Liyan Miao · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-16
Primary Completion
2023-01-05
Completion
2023-01-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06523088 on ClinicalTrials.gov